Guyton, J. R., Goldberg, R. B., Mazzone, T., Weinstock, R. S., Polis, A., Rosenberg, E., … Tershakovec, A. M. (2007). PO23-755 EZETIMIBE/SIMVASTATIN MORE FAVORABLY INFLUENCES LIPOPROTEIN/APOLIPOPROTEIN RATIOS THAN ATORVASTATIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES. In Atherosclerosis Supplements (Vol. 8, pp. 201–201). Elsevier BV. https://doi.org/10.1016/s1567-5688(07)71765-8

Guyton, J. R., R. B. Goldberg, T. Mazzone, R. S. Weinstock, A. Polis, E. Rosenberg, P. Edwards, and A. M. Tershakovec. “PO23-755 EZETIMIBE/SIMVASTATIN MORE FAVORABLY INFLUENCES LIPOPROTEIN/APOLIPOPROTEIN RATIOS THAN ATORVASTATIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES.” In Atherosclerosis Supplements, 8:201–201. Elsevier BV, 2007. https://doi.org/10.1016/s1567-5688(07)71765-8.

Guyton JR, Goldberg RB, Mazzone T, Weinstock RS, Polis A, Rosenberg E, et al. PO23-755 EZETIMIBE/SIMVASTATIN MORE FAVORABLY INFLUENCES LIPOPROTEIN/APOLIPOPROTEIN RATIOS THAN ATORVASTATIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES. In: Atherosclerosis Supplements. Elsevier BV; 2007. p. 201–201.

Guyton, J. R., et al. “PO23-755 EZETIMIBE/SIMVASTATIN MORE FAVORABLY INFLUENCES LIPOPROTEIN/APOLIPOPROTEIN RATIOS THAN ATORVASTATIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES.” Atherosclerosis Supplements, vol. 8, no. 1, Elsevier BV, 2007, pp. 201–201. Crossref, doi:10.1016/s1567-5688(07)71765-8.

Guyton JR, Goldberg RB, Mazzone T, Weinstock RS, Polis A, Rosenberg E, Edwards P, Tershakovec AM. PO23-755 EZETIMIBE/SIMVASTATIN MORE FAVORABLY INFLUENCES LIPOPROTEIN/APOLIPOPROTEIN RATIOS THAN ATORVASTATIN MONOTHERAPY IN PATIENTS WITH TYPE 2 DIABETES. Atherosclerosis Supplements. Elsevier BV; 2007. p. 201–201.